Immune checkpoint receptors in regulating immune reactivity in rheumatic disease

Arthritis Research and Therapy

Volumn 16, Issue 1, 2014, Pages

  Ceeraz, Sabrina ^a   Nowak, Elizabeth C ^a   Burns, Christopher M ^a   Noelle, Randolph J ^a,b,c  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b GUY S HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALPHA INTERFERON; B7 ANTIGEN; CD134 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD40 LIGAND; CD69 ANTIGEN; CD70 ANTIGEN; CD8 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; IMMUNE CHECKPOINT REGULATOR; IMMUNOGLOBULIN G; INDUCIBLE T CELL COSTIMULATOR LIGAND; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 2; INTERLEUKIN 4; METHOTREXATE; REGULATOR PROTEIN; RETINOID; RITUXIMAB; TORALIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIRHEUMATIC AGENT; LYMPHOCYTE ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR;

ANTIBODY PRODUCTION; CELL ACTIVATION; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; DISEASE PREDISPOSITION; DRUG TREATMENT FAILURE; GENETIC POLYMORPHISM; HUMAN; HUMORAL IMMUNITY; IMMUNOREACTIVITY; JUVENILE RHEUMATOID ARTHRITIS; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE FUNCTION; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHOTOTHERAPY; PROTEIN BINDING; PROTEIN EXPRESSION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; BIOLOGICAL MODEL; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE ACTIVATION; METABOLISM; RHEUMATIC DISEASES; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANTIRHEUMATIC AGENTS; COSTIMULATORY AND INHIBITORY T-CELL RECEPTORS; HUMANS; INFLAMMATION; LYMPHOCYTE ACTIVATION; MODELS, IMMUNOLOGICAL; RECEPTORS, ANTIGEN, T-CELL; RHEUMATIC DISEASES; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 85003273937     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-014-0469-1     Document Type: Review

References (142)

1. Jenkins MK: The ups and downs of T cell costimulation. Immunity 1994, 1:443-446.
2. Ceeraz S, Nowak EC, Noelle RJ: B7 family checkpoint regulators in immune regulation and disease. Trends Immunol 2013, 34:556-563.
3. Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, Haldeman B, Ostrander CD, Kaifu T, Chabannon C, Moretta A, West R, Xu W, Vivier E, Levin SD: The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 2009, 206:1495-1503.
4. Meylan F, Richard AC, Siegel RM: TL1A and DR3, a TNF family ligand-receptor pair that promotes lymphocyte costimulation, mucosal hyperplasia, and autoimmune inflammation. Immunol Rev 2011, 244:188-196.
5. Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, Hong JS, Perry JW, Chen SF, Zhou JX, Cho YH, Ullrich S, Kanakaraj P, Carrell J, Boyd E, Olsen HS, Hu G, Pukac L, Liu D, Ni J, Kim S, Gentz R, Feng P, Moore PA, Ruben SM, Wei P: TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002, 16:479-492.
6. Watts TH: TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005, 23:23-68.
7. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ: Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 2009, 229:152-172.
8. Pardoll D, Drake C: Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med 2012, 209:201-209.
9. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
10. Alvarez-Quiroga C, Abud-Mendoza C, Doniz-Padilla L, Juarez-Reyes A, Monsivais-Urenda A, Baranda L, Gonzalez-Amaro R: CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis. J Clin Immunol 2011, 31:588-595.
11. Wen Z, Xu L, Chen X, Xu W, Yin Z, Gao X, Xiong S: Autoantibody induction by DNA-containing immune complexes requires HMGB1 with the TLR2/microRNA-155 pathway. J Immunol 2013, 190:5411-5422.
12. Swigris JJ, Fischer A, Gillis J, Meehan RT, Brown KK: Pulmonary and thrombotic manifestations of systemic lupus erythematosus. Chest 2008, 133:271-280.
13. Deane KD, El-Gabalawy H: Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE. Nat Rev Rheumatol 2014, 10:212-228.
14. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA: Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 2009, 18:767-776.
15. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG: Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010, 62:222-233.
16. Eisenstein M: Approval on a knife edge. Nat Biotechnol 2012, 30:26-29.
17. Townsend MJ, Monroe JG, Chan AC: B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev 2010, 237:264-283.
18. Desai-Mehta A, Mao C, Rajagopalan S, Robinson T, Datta SK: Structure and specificity of T cell receptors expressed by potentially pathogenic anti-DNA autoantibody-inducing T cells in human lupus. J Clin Invest 1995, 95:531-541.
19. Valencia X, Yarboro C, Illei G, Lipsky PE: Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007, 178:2579-2588.
20. Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK: High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007, 8:492-502.
21. Finck BK, Linsley PS, Wofsy D: Treatment of murine lupus with CTLA4Ig. Science 1994, 265:1225-1227.
22. Daikh DI, Wofsy D: Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001, 166:2913-2916.
23. Wang X, Huang W, Mihara M, Sinha J, Davidson A: Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus. J Immunol 2002, 168:2046-2053.
24. Schiffer L, Bethunaickan R, Ramanujam M, Huang W, Schiffer M, Tao H, Madaio MP, Bottinger EP, Davidson A: Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J Immunol 2008, 180:1938-1947.
25. Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, Bae SC, Sigal L, Becker JC, Kelly S, Raghupathi K, Li T, Peng Y, Kinaszczuk M, Nash P: The efficacy and safety of abatacept in patients with non-lifethreatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, doubleblind, placebo-controlled trial. Arthritis Rheum 2010, 62:3077-3087.
26. Hebbar M, Jeannin P, Magistrelli G, Hatron PY, Hachulla E, Devulder B, Bonnefoy JY, Delneste Y: Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjogren's syndrome and systemic sclerosis. Clin Exp Immunol 2004, 136:388-392.
27. Lee YH, Harley JB, Nath SK: CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-analysis. Hum Genet 2005, 116:361-367.
28. Matsui T, Kurokawa M, Kobata T, Oki S, Azuma M, Tohma S, Inoue T, Yamamoto K, Nishioka K, Kato T: Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases. J Immunol 1999, 162:4328-4335.
29. Shin JI, Park SJ, Saleem MA: The beneficial effect of abatacept on lupus nephritis: the role of podocyte beta1-integrin stabilization and Tregs repopopulation? Arthritis Rheumatol 2014, 66:2913-2914.
30. + T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosus. Clin Exp Immunol 2006, 145:235-242.
31. Shi Q, Gao ZY, Xie F, Wang LF, Gu YP, Yang TJ, Huang L, Qian QH, Qiu YH: A novel monoclonal antibody against human CD80 and its immune protection in a mouse lupus-like disease. Int J Immunopathol Pharmacol 2011, 24:583-593.
32. Hutloff A, Buchner K, Reiter K, Baelde HJ, Odendahl M, Jacobi A, Dorner T, Kroczek RA: Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum 2004, 50:3211-3220.
33. Her M, Kim D, Oh M, Jeong H, Choi I: Increased expression of soluble inducible costimulator ligand (ICOSL) in patients with systemic lupus erythematosus. Lupus 2009, 18:501-507.
34. Yang JH, Zhang J, Cai Q, Zhao DB, Wang J, Guo PE, Liu L, Han XH, Shen Q: Expression and function of inducible costimulator on peripheral blood T cells in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005, 44:1245-1254.
35. Tada Y, Koarada S, Tomiyoshi Y, Morito F, Mitamura M, Haruta Y, Ohta A, Nagasawa K: Role of inducible costimulator in the development of lupus in MRL/lpr mice. Clin Immunol 2006, 120:179-188.
36. Iwai H, Abe M, Hirose S, Tsushima F, Tezuka K, Akiba H, Yagita H, Okumura K, Kohsaka H, Miyasaka N, Azuma M: Involvement of inducible costimulator-B7 homologous protein costimulatory pathway in murine lupus nephritis. J Immunol 2003, 171:2848-2854.
37. Keir ME, Butte MJ, Freeman GJ, Sharpe AH: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26:677-704.
38. Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V, Brookes AJ, Tentler D, Kristjansdottir H, Grondal G, Bolstad AI, Svenungsson E, Lundberg I, Sturfelt G, Jönssen A, Truedsson L, Lima G, Alcocer-Varela J, Jonsson R, Gyllensten UB, Harley JB, Alarcón-Segovia D, Steinsson K, Alarcón-Riquelme ME: A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002, 32:666-669.
39. Nishimura H, Nose M, Hiai H, Minato N, Honjo T: Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999, 11:141-151.
40. +PD-1+ T cells and relieves the lupus-like nephritis of NZB/ W F1 mice. J Immunol 2010, 184:2337-2347.
41. + regulatory T cells protecting from lupus-like disease. J Immunol 2013, 190:5402-5410.
42. + T cells that protect from lupus-like disease. J Immunol 2010, 185:6563-6571.
43. Mehta J, Genin A, Brunner M, Scalzi LV, Mishra N, Beukelman T, Cron RQ: Prolonged expression of CD154 on CD4 T cells from pediatric lupus patients correlates with increased CD154 transcription, increased nuclear factor of activated T cell activity, and glomerulonephritis. Arthritis Rheum 2010, 62:2499-2509.
44. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK: Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996, 97:2063-2073.
45. Koshy M, Berger D, Crow MK: Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996, 98:826-837.
46. Kato K, Santana-Sahagun E, Rassenti LZ, Weisman MH, Tamura N, Kobayashi S, Hashimoto H, Kipps TJ: The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest 1999, 104:947-955.
47. Early GS, Zhao W, Burns CM: Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black × New Zealand white mice. Response correlates with the absence of an anti-antibody response. J Immunol 1996, 157:3159-3164.
48. Quezada SA, Eckert M, Adeyi OA, Schned AR, Noelle RJ, Burns CM: Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis. Arthritis Rheum 2003, 48:2541-2554.
49. Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D, IDEC-131 Lupus Study Group: Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:3251-3258.
50. Grammer AC, Slota R, Fischer R, Gur H, Girschick H, Yarboro C, Illei GG, Lipsky PE: Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 2003, 112:1506-1520.
51. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, Vaishnaw A, BG9588 Lupus Nephritis Trial Group: A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003, 48:719-727.
52. Hausding M, Jurk K, Daub S, Kroller-Schon S, Stein J, Schwenk M, Oelze M, Mikhed Y, Kerahrodi JG, Kossmann S, Jansen T, Schulz E, Wenzel P, Reske-Kunz AB, Becker C,Munzel T, Grabbe S, Daiber A: CD40L contributes to angiotensin II-induced pro-thrombotic state, vascular inflammation, oxidative stress and endothelial dysfunction. Basic Res Cardiol 2013, 108:386.
53. Xie JH, Yamniuk AP, Borowski V, Kuhn R, Susulic V, Rex-Rabe S, Yang X, Zhou X, Zhang Y, Gillooly K, Brosius R, Ravishankar R, Waggie K, Mink K, Price L, Rehfuss R, Tamura J, An Y, Cheng L, Abramczyk B, Ignatovich O, Drew P, Grant S, Bryson JW, Suchard S, Salter-Cid L, Nadler S, Suri A: Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseases. J Immunol 2014, 192:4083-4092.
54. Aten J, Roos A, Claessen N, Schilder-Tol EJ, Ten Berge IJ, Weening JJ: Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. J Am Soc Nephrol 2000, 11:1426-1438.
55. Zhou YB, Ye RG, Li YJ, Xie CM, Wu YH: Effect of anti-CD134L mAb and CTLA4Ig on ConA-induced proliferation, Th cytokine secretion, and anti-dsDNA antibody production in spleen cells from lupus-prone BXSB mice. Autoimmunity 2008, 41:395-404.
56. Zhou YB, Ye RG, Li YJ, Xie CM: Targeting the CD134-CD134L interaction using anti-CD134 and/or rhCD134 fusion protein as a possible strategy to prevent lupus nephritis. Rheumatol Int 2009, 29:417-425.
57. Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M: Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 1990, 33:1665-1673.
58. Wei C, Anolik J, Cappione A, Zheng B, Pugh-Bernard A, Brooks J, Lee EH, Milner EC, Sanz I: A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 2007, 178:6624-6633.
59. Jacobi AM, Odendahl M, Reiter K, Bruns A, Burmester GR, Radbruch A, Valet G, Lipsky PE, Dorner T: Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003, 48:1332-1342.
60. Vinay DS, Kim JD, Asai T, Choi BK, Kwon BS: Absence of 4 1BB gene function exacerbates lacrimal gland inflammation in autoimmune-prone MRL-Faslpr mice. Invest Ophthalmol Vis Sci 2007, 48:4608-4615.
61. Sun Y, Chen HM, Subudhi SK, Chen J, Koka R, Chen L, Fu YX: Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med 2002, 8:1405-1413.
62. Foell J, Strahotin S, O'Neil SP, McCausland MM, Suwyn C, Haber M, Chander PN, Bapat AS, Yan XJ, Chiorazzi N, Hoffmann MK, Mittler RS: CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice. J Clin Invest 2003, 111:1505-1518.
63. Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, Williams B, Gabriel S, Lassere M, Johns N, Buchbinder R, Woolf A, March L: The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 2014, 73:1316-1322.
64. Plenge RM, Padyukov L, Remmers EF, Purcell S, Lee AT, Karlson EW, Wolfe F, Kastner DL, Alfredsson L, Altshuler D, Gregersen PK, Klareskog L, Rioux JD: Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet 2005, 77:1044-1060.
65. Flores-Borja F, Jury EC, Mauri C, Ehrenstein MR: Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci U S A 2008, 105:19396-19401.
66. Cao J, Zou L, Luo P, Chen P, Zhang L: Increased production of circulating soluble co-stimulatory molecules CTLA-4, CD28 and CD80 in patients with rheumatoid arthritis. Int Immunopharmacol 2012, 14:585-592.
67. Scarsi M, Ziglioli T, Airo P: Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis. J Rheumatol 2011, 38:2105-2111.
68. + cells in patients with rheumatoid arthritis chronically treated with abatacept. Int J Rheum Dis 2013, 16:469-471.
69. Kong EK, Prokunina-Olsson L, Wong WH, Lau CS, Chan TM, Alarcon-Riquelme M, Lau YL: A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis Rheum 2005, 52:1058-1062.
70. + T cells in rheumatoid arthritis. Inflammation 2014, 37:116-121.
71. Raptopoulou AP, Bertsias G, Makrygiannakis D, Verginis P, Kritikos I, Tzardi M, Klareskog L, Catrina AI, Sidiropoulos P, Boumpas DT: The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum 2010, 62:1870-1880.
72. Hamel KM, Cao Y, Wang Y, Rodeghero R, Kobezda T, Chen L, Finnegan A: B7-H1 expression on non-B and non-T cells promotes distinct effects on T-and B-cell responses in autoimmune arthritis. Eur J Immunol 2010, 40:3117-3127.
73. Wang G, Hu P, Yang J, Shen G, Wu X: The effects of PDL-Ig on collageninduced arthritis. Rheumatol Int 2011, 31:513-519.
74. Kamimura Y, Kobori H, Piao J, Hashiguchi M, Matsumoto K, Hirose S, Azuma M: Possible involvement of soluble B7-H4 in T cell-mediated inflammatory immune responses. Biochem Biophys Res Commun 2009, 389:349-353.
75. Azuma T, Zhu G, Xu H, Rietz AC, Drake CG, Matteson EL, Chen L: Potential role of decoy B7-H4 in the pathogenesis of rheumatoid arthritis: a mouse model informed by clinical data. PLoS Med 2009, 6:e1000166.
76. Shang Y, Guo G, Cui Q, Li J, Ruan Z, Chen Y: The expression and anatomical distribution of BTLA and its ligand HVEM in rheumatoid synovium. Inflammation 2012, 35:1102-1112.
77. Guo G, Shang Y, Zhu G, Bao X, Xu S, Chen Y: The expression and distribution of immunomodulatory proteins B7-H1, B7-DC, B7-H3, and B7-H4 in rheumatoid synovium. Clin Rheumatol 2012, 31:271-281.
78. Pierer M, Schulz A, Rossol M, Kendzia E, Kyburz D, Haentzschel H, Baerwald C, Wagner U: Herpesvirus entry mediator-Ig treatment during immunization aggravates rheumatoid arthritis in the collagen-induced arthritis model. J Immunol 2009, 182:3139-3145.
79. Garcia-Bermudez M, Gonzalez-Juanatey C, Lopez-Mejias R, Teruel M, Corrales A, Miranda-Filloy JA, Castaneda S, Balsa A, Fernandez-Gutierrez B, Gonzalez-Alvaro I, omez-Vaquero C, Blanco R, Llorca J, Martin J, Gonzalez-Gay MA: Study of association of CD40-CD154 gene polymorphisms with disease susceptibility and cardiovascular risk in Spanish rheumatoid arthritis patients. PLoS One 2012, 7:e49214.
80. MacDonald KP, Nishioka Y, Lipsky PE, Thomas R: Functional CD40 ligand is expressed by T cells in rheumatoid arthritis. J Clin Invest 1997, 100:2404-2414.
81. Tamura N, Kobayashi S, Kato K, Bando H, Haruta K, Oyanagi M, Kuriyama M, Kipps TJ, Hashimoto H: Soluble CD154 in rheumatoid arthritis: elevated plasma levels in cases with vasculitis. J Rheumatol 2001, 28:2583-2590.
82. Liao J, Liang G, Xie S, Zhao H, Zuo X, Li F, Chen J, Zhao M, Chan TM, Lu Q: CD40L demethylation in CD4 (+) T cells from women with rheumatoid arthritis. Clin Immunol 2012, 145:13-18.
83. Kyburz D, Carson DA, Corr M: The role of CD40 ligand and tumor necrosis factor alpha signaling in the transgenic K/BxN mouse model of rheumatoid arthritis. Arthritis Rheum 2000, 43:2571-2577.
84. Tellander AC, Michaelsson E, Brunmark C, Andersson M: Potent adjuvant effect by anti-CD40 in collagen-induced arthritis. Enhanced disease is accompanied by increased production of collagen type-II reactive IgG2a and IFN-gamma. J Autoimmun 2000, 14:295-302.
85. Andreakos E, Rauchhaus U, Stavropoulos A, Endert G, Wendisch V, Benahmed AS, Giaglis S, Karras J, Lee S, Gaus H, Bennett CF, Williams RO, Sideras P, Panzner S: Amphoteric liposomes enable systemic antigen-presenting cell-directed delivery of CD40 antisense and are therapeutically effective in experimental arthritis. Arthritis Rheum 2009, 60:994-1005.
86. Zheng X, Suzuki M, Zhang X, Ichim TE, Zhu F, Ling H, Shunnar A, Wang MH, Garcia B, Inman RD, Min WP: RNAi-mediated CD40-CD154 interruption promotes tolerance in autoimmune arthritis. Arthritis Res Ther 2010, 12:R13.
87. Michel J, Langstein J, Hofstadter F, Schwarz H: A soluble form of CD137 (ILA/4-1BB), a member of the TNF receptor family, is released by activated lymphocytes and is detectable in sera of patients with rheumatoid arthritis. Eur J Immunol 1998, 28:290-295.
88. Foell JL, Diez-Mendiondo BI, Diez OH, Holzer U, Ruck P, Bapat AS, Hoffmann MK, Mittler RS, Dannecker GE: Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance. Immunology 2004, 113:89-98.
89. Seo SK, Choi JH, Kim YH, Kang WJ, Park HY, Suh JH, Choi BK, Vinay DS, Kwon BS: 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med 2004, 10:1088-1094.
90. Brugnoni D, Bettinardi A, Malacarne F, Airo P, Cattaneo R: CD134/OX40 expression by synovial fluid CD4+ T lymphocytes in chronic synovitis. Br J Rheumatol 1998, 37:584-585.
91. Passacantando A, Parzanese I, Rascente M, Petrucci C, Minisola G, Tonietti G: Synovial fluid OX40T lymphocytes of patients with rheumatoid arthritis display a Th2/Th0 polarization. Int J Immunopathol Pharmacol 2006, 19:499-505.
92. + T cells in adjuvant arthritis. Arthritis Res Ther 2005, 7:R604-R615.
93. Findlay EG, Danks L, Madden J, Cavanagh MM, McNammee K, McCann F, Snelgrove RJ, Shaw S, Feldmann M, Taylor PC, Horwood NJ, Hussell T: OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis. Proc Natl Acad Sci U S A 2014, 111:2289-2294.
94. Lee WW, Yang ZZ, Li G, Weyand CM, Goronzy JJ: Unchecked CD70 expression on T cells lowers threshold for T cell activation in rheumatoid arthritis. J Immunol 2007, 179:2609-2615.
95. Oflazoglu E, Boursalian TE, Zeng W, Edwards AC, Duniho S, McEarchern JA, Law CL, Gerber HP, Grewal IS: Blocking of CD27-CD70 pathway by anti-CD70 antibody ameliorates joint disease in murine collagen-induced arthritis. J Immunol 2009, 183:3770-3777.
96. + naive T cells and changes in T cell homeostasis in a case of acute exacerbation of juvenile idiopathic arthritis: a case comparison study. J Med Case Rep 2013, 7:135.
97. + T cells in juvenile idiopathic arthritis. Arthritis Rheum 2013, 65:2201-2210.
98. Smolewska E, Stanczyk J, Brozik H, Biernacka-Zielinska M, Cebula B, Robak T, Smolewski P: Distribution and clinical significance of blood dendritic cells in children with juvenile idiopathic arthritis. Ann Rheum Dis 2008, 67:762-768.
99. Goldzweig O, Hashkes PJ: Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy. Drug Des Devel Ther 2011, 5:61-70.
100. Albers HM, Reinards TH, Brinkman DM, Kamphuis SS, van Rossum MA, Hoppenreijs EP, Girschick HJ, Wouters C, Saurenmann RK, Bakker E, Verduijn W, Slagboom P, Huizinga TW, Toes RE, Houwing-Duistermaat JJ, ten Cate R, Schilham MW: Genetic variation in VTCN1 (B7-H4) is associated with course of disease in juvenile idiopathic arthritis. Ann Rheum Dis 2014, 73:1198-1201.
101. Prahalad S, Martins TB, Tebo AE, Whiting A, Clifford B, Zeft AS, McNally B, Bohnsack JF, Hill HR: Elevated serum levels of soluble CD154 in children with juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2008, 6:8.
102. Bolstad AI, Jonsson R: Genetic aspects of Sjogren's syndrome. Arthritis Res 2002, 4:353-359.
103. Gordon TP, Bolstad AI, Rischmueller M, Jonsson R, Waterman SA: Autoantibodies in primary Sjogren's syndrome: new insights into mechanisms of autoantibody diversification and disease pathogenesis. Autoimmunity 2001, 34:123-132.
104. +CD28-T cells correlates with clinical activity in primary Sjogren's syndrome. Cell Immunol 2012, 278:143-151.
105. Saegusa K, Ishimaru N, Yanagi K, Haneji N, Nishino M, Azuma M, Saito I, Hayashi Y: Autoantigen-specific CD4+CD28low T cell subset prevents autoimmune exocrinopathy in murine Sjogren's syndrome. J Immunol 2000, 165:2251-2257.
106. Downie-Doyle S, Bayat N, Rischmueller M, Lester S: Influence of CTLA4 haplotypes on susceptibility and some extraglandular manifestations in primary Sjogren's syndrome. Arthritis Rheum 2006, 54:2434-2440.
107. Gottenberg JE, Loiseau P, Azarian M, Chen C, Cagnard N, Hachulla E, Puechal X, Sibilia J, Charron D, Mariette X, Miceli-Richard C: CTLA-4 + 49A/G and CT60 gene polymorphisms in primary Sjogren syndrome. Arthritis Res Ther 2007, 9:R24.
108. Bolstad AI, Eiken HG, Rosenlund B, Alarcon-Riquelme ME, Jonsson R: Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic T lymphocyte-associated antigen 4, and programmed cell death 1 in primary Sjogren's syndrome. Arthritis Rheum 2003, 48:174-185.
109. Manoussakis MN, Dimitriou ID, Kapsogeorgou EK, Xanthou G, Paikos S, Polihronis M, Moutsopoulos HM: Expression of B7 costimulatory molecules by salivary gland epithelial cells in patients with Sjogren's syndrome. Arthritis Rheum 1999, 42:229-239.
110. Matsumura R, Umemiya K, Goto T, Nakazawa T, Kagami M, Tomioka H, Tanabe E, Sugiyama T, Sueishi M: Glandular and extraglandular expression of costimulatory molecules in patients with Sjogren's syndrome. Ann Rheum Dis 2001, 60:473-482.
111. Tsunawaki S, Nakamura S, Ohyama Y, Sasaki M, Ikebe-Hiroki A, Hiraki A, Kadena T, Kawamura E, Kumamaru W, Shinohara M, Shirasuna K: Possible function of salivary gland epithelial cells as nonprofessional antigenpresenting cells in the development of Sjogren's syndrome. J Rheumatol 2002, 29:1884-1896.
112. Saegusa K, Ishimaru N, Yanagi K, Haneji N, Nishino M, Azuma M, Saito I, Hayashi Y: Treatment with anti-CD86 costimulatory molecule prevents the autoimmune lesions in murine Sjogren's syndrome (SS) through up-regulated Th2 response. Clin Exp Immunol 2000, 119:354-360.
113. Yin H, Nguyen CQ, Samuni Y, Uede T, Peck AB, Chiorini JA: Local delivery of AAV2-CTLA4IgG decreases sialadenitis and improves gland function in the C57BL/6NOD-Aec1Aec2 mouse model of Sjogren's syndrome. Arthritis Res Ther 2012, 14:R40.
114. Kobayashi M, Kawano S, Hatachi S, Kurimoto C, Okazaki T, Iwai Y, Honjo T, Tanaka Y, Minato N, Komori T, Maeda S, Kumagai S: Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjogren's syndrome. J Rheumatol 2005, 32:2156-2163.
115. Gong YZ, Nititham J, Taylor K, Miceli-Richard C, Sordet C, Wachsmann D, Bahram S, Georgel P, Criswell LA, Sibilia J, Mariette X, Alsaleh G, Gottenberg JE: Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sjogren's syndrome. J Autoimmun 2014, 51:57-66.
116. Oya Y, Watanabe N, Owada T, Oki M, Hirose K, Suto A, Kagami S, Nakajima H, Kishimoto T, Iwamoto I, Murphy TL, Murphy KM, Saito Y: Development of autoimmune hepatitis-like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator. Arthritis Rheum 2008, 58:2498-2510.
117. Goules A, Tzioufas AG, Manousakis MN, Kirou KA, Crow MK, Routsias JG: Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. J Autoimmun 2006, 26:165-171.
118. Ping L, Ogawa N, Zhang Y, Sugai S, Masaki Y, Weiguo X: p38 mitogenactivated protein kinase and nuclear factor-kappaB facilitate CD40-mediated salivary epithelial cell death. J Rheumatol 2012, 39:1256-1264.
119. Roescher N, Vosters JL, Lai Z, Uede T, Tak PP, Chiorini JA: Local administration of soluble CD40:Fc to the salivary glands of non-obese diabetic mice does not ameliorate autoimmune inflammation. PLoS One 2012, 7:e51375.
120. Nordmark G, Kristjansdottir G, Theander E, Appel S, Eriksson P, Vasaitis L, Kvarnstrom M, Delaleu N, Lundmark P, Lundmark A, Sjowall C, Brun JG, Jonsson MV, Harboe E, Goransson LG, Johnsen SJ, Soderkvist P, Eloranta ML, Alm G, Baecklund E, Wahren-Herlenius M, Omdal R, Ronnblom L, Jonsson R, Syvanen AC: Association of EBF1, FAM167A (C8orf13)-BLK and TNFSF4 gene variants with primary Sjogren's syndrome. Genes Immun 2011, 12:100-109.
121. Hansen A, Odendahl M, Reiter K, Jacobi AM, Feist E, Scholze J, Burmester GR, Lipsky PE, Dorner T: Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 2002, 46:2160-2171.
122. Hansen A, Gosemann M, Pruss A, Reiter K, Ruzickova S, Lipsky PE, Dorner T: Abnormalities in peripheral B cell memory of patients with primary Sjogren's syndrome. Arthritis Rheum 2004, 50:1897-1908.
123. Yin H, Zhao M, Wu X, Gao F, Luo Y, Ma L, Liu S, Zhang G, Chen J, Li F, Zuo X, Lu Q: Hypomethylation and overexpression of CD70 (TNFSF7) in CD4+ T cells of patients with primary Sjogren's syndrome. J Dermatol Sci 2010, 59:198-203.
124. Nestle FO, Kaplan DH, Barker J: Psoriasis. N Engl J Med 2009, 361:496-509.
125. Rahman M, Alam K, Ahmad MZ, Gupta G, Afzal M, Akhter S, Kazmi I, Jyoti, Ahmad FJ, Anwar F: Classical to current approach for treatment of psoriasis: a review. Endocr Metab Immune Disord Drug Targets 2012, 12:287-302.
126. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, Menter A, Lowe NJ, Krueger G, Brown MJ, Weiner RS, Birkhofer MJ, Warner GL, Berry KK, Linsley PS, Krueger JG, Ochs HD, Kelley SL, Kang S: CTLA4Igmediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999, 103:1243-1252.
127. Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang S, Lebwohl MG, Guzzo CA, Jegasothy BV, Linsley PS, Krueger JG: Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000, 192:681-694.
128. Mease P, Genovese MC, Gladstein G, Kivitz AJ, Ritchlin C, Tak PP, Wollenhaupt J, Bahary O, Becker JC, Kelly S, Sigal L, Teng J, Gladman D: Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011, 63:939-948.
129. Altmeyer MD, Kerisit KG, Boh EE: Therapeutic hotline. Abatacept: our experience of use in two patients with refractory psoriasis and psoriatic arthritis. Dermatol Ther 2011, 24:287-290.
130. Ursini F, Naty S, Russo E, Grembiale RD: Abatacept in psoriatic arthritis: case report and short review. J Pharmacol Pharmacother 2013, 4:S29-S32.
131. Ohta Y, Hamada Y: In situ expression of CD40 and CD40 ligand in psoriasis. Dermatology 2004, 209:21-28.
132. Daoussis D, Antonopoulos I, Andonopoulos AP, Liossis SN: Increased expression of CD154 (CD40L) on stimulated T-cells from patients with psoriatic arthritis. Rheumatology (Oxford) 2007, 46:227-231.
133. Fleischmajer R, Perlish JS, Reeves JR: Cellular infiltrates in scleroderma skin. Arthritis Rheum 1977, 20:975-984.
134. Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P: Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992, 166:255-263.
135. Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP: Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 1984, 27:645-653.
136. Hamaguchi Y: Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J Dermatol 2010, 37:42-53.
137. Fineschi S, Cozzi F, Burger D, Dayer JM, Meroni PL, Chizzolini C: Antifibroblast antibodies detected by cell-based ELISA in systemic sclerosis enhance the collagenolytic activity and matrix metalloproteinase-1 production in dermal fibroblasts. Rheumatology (Oxford) 2007, 46:1779-1785.
138. Fineschi S, Goffin L, Rezzonico R, Cozzi F, Dayer JM, Meroni PL, Chizzolini C: Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4. Arthritis Rheum 2008, 58:3913-3923.
139. Lian X, Xiao R, Hu X, Kanekura T, Jiang H, Li Y, Wang Y, Yang Y, Zhao M, Lu Q: DNA demethylation of CD40l in CD4+ T cells from women with systemic sclerosis: a possible explanation for female susceptibility. Arthritis Rheum 2012, 64:2338-2345.
140. Kawai M, Masuda A, Kuwana M: A CD40-CD154 interaction in tissue fibrosis. Arthritis Rheum 2008, 58:3562-3573.
141. Jiang H, Xiao R, Lian X, Kanekura T, Luo Y, Yin Y, Zhang G, Yang Y, Wang Y, Zhao M, Lu Q: Demethylation of TNFSF7 contributes to CD70 overexpression in CD4+ T cells from patients with systemic sclerosis. Clin Immunol 2012, 143:39-44.
142. Gourh P, Arnett FC, Tan FK, Assassi S, Divecha D, Paz G, McNearney T, Draeger H, Reveille JD, Mayes MD, Agarwal SK: Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis. Ann Rheum Dis 2010, 69:550-555.